Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy

Status Recruiting

Clinical Trial Summary

The cornea forms our "window to the world". Hence, its transparency is of utmost importance for vision. Corneal endothelium plays a central role in the maintenance of a transparent corneal stroma. It limits stromal fluid uptake from the anterior chamber of the eye through the formation of tight junctions. Simultaneously, fluid is actively transported from corneal stroma into the anterior chamber. This maintains the corneal stroma in a state of relative dehydration, thereby ensuring a constant distance of stromal collagen lamellae to each other, which in turn forms the basis for transparency of this tissue. If however corneal endothelial function is impaired, stromal swelling leads to corneal clouding and loss of vision.

Fuchs endothelial corneal dystrophy represents the most common form of corneal dystrophy. It occurs sporadically, however in some cases autosomal dominant inheritance has been described. This condition leads to progressive loss of corneal endothelium (typically around the age of 50-60 years), causing visual impairment due to swelling and opacification of corneal stroma.

Cell culture experiments have been able to show that chemical inhibitors of Rho-Kinase promote corneal endothelial cell proliferation and reduce apoptosis, while topical application in an animal model promoted corneal endothelial wound healing. This has prompted the notion of using topical Rho-kinase-inhibitor treatment to support endothelial cell regeneration in Fuchs endothelial corneal dystrophy.

Since September 2014, Rho-kinase-inhibitor eye drops (ripasudil) are clinically available in Japan for reduction of intraocular pressure in Glaucoma patients. Ripasudil eye drops therefore represent a strong candidate for safe and effective adjunctive treatment in patients with Fuchs corneal endothelial cell dystrophy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03575130
Study type	Interventional
Source	University of Erlangen-Nürnberg Medical School
Contact
Status	Recruiting
Phase	Phase 2
Start date	June 5, 2018
Completion date	December 31, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03248037` - Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation	Phase 3
Recruiting	`NCT03275896` - Evaluation of the Efficacy of Descemet Membrane Transplantation for the Treatment of Fuchs' Endothelial Dystrophy	Early Phase 1
Completed	`NCT02332109` - ODM 5 in the Treatment of Corneal Edematous Fuchs' Endothelial Dystrophy	N/A
Completed	`NCT02470793` - Technique And Results In Endothelial Keratoplasty	N/A
Recruiting	`NCT01206127` - DSAEK- Postoperative Positioning and Transplant Dislocation	N/A
Recruiting	`NCT03407755` - Air Versus SF6 for Descemet's Membrane Endothelial Keratoplasty (DMEK)	N/A
Completed	`NCT04140422` - Eye Drops for Early Morning-Associated Corneal Swelling of the Cornea	N/A
Recruiting	`NCT06048380` - The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract Surgery	Phase 3
Completed	`NCT02793310` - DMEK Versus DSAEK Study	N/A
Completed	`NCT01795001` - The Molecular Pathogenesis of Late-onset Fuchs' Endothelial Corneal Dystrophy
Completed	`NCT04057053` - Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty	Early Phase 1
Terminated	`NCT01361282` - Using the Optovue OCT to Select IOL Power	N/A
Completed	`NCT02542644` - Assessment of Corneal Graft Attachment in Patients With Fuchs Endothelial Corneal Dystrophy Following DMEK Using Ultra-high Resolution OCT	N/A
Recruiting	`NCT04191629` - Phase 1 Study to Evaluate the Safety and Tolerability of EO1404 in the Treatment of Corneal Edema	Phase 1
Completed	`NCT05399095` - Supine Positioning for Graft Attachment After Descemet Membrane Endothelial Keratoplasty	N/A
Completed	`NCT04752020` - Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty	Early Phase 1
Not yet recruiting	`NCT05716945` - The OPTIMISE Study	Phase 4
Recruiting	`NCT02118922` - A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
Completed	`NCT04420429` - The Effect Of Preoperative Parameters On Success After DMEK Surgery
Withdrawn	`NCT04018417` - Evaluation of Amphotericin B in Optisol-GS for Prevention of Post-Keratoplasty Fungal Infections.	Phase 2/Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.